language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
ATRATR

$125.51

-1.34
arrow_drop_down1.06%
Current Market·update15 Jan 2026 19:09
Day's Range
124.56-127.22
52-week Range
103.23-164.28

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-02-05
Next Earnings TimeAfter Market Close
Volume174.41K
Average Volume 30d588.37K

AI ATR Summary

Powered by LiveAI
💰
29.58
Valuation (P/E Ratio)
The P/E ratio is higher than the industry average, suggesting potential overvaluation or high growth expectations.
📈
0.152
EPS Growth (YoY)
Positive year-over-year EPS growth indicates improving profitability. (Calculated from Q4 2023 vs Q4 2024 reported EPS estimates)
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
75

AptarGroup demonstrates solid fundamental performance with consistent profitability and a healthy balance sheet. Thematic tailwinds in essential consumer and pharmaceutical markets provide stability, though recent technical indicators suggest a neutral to cautious short-term outlook.

Neutral

Thematic

65

AptarGroup operates in stable, albeit less dynamic, end markets such as consumer products, beauty, and pharmaceuticals. While these sectors offer resilience, they may not capture the high-growth potential of emerging technology themes.

Strong

Fundamental

80

AptarGroup demonstrates strong financial health with robust profitability, consistent revenue growth, and a well-managed balance sheet. Its valuation metrics are reasonable given its stable market position and earnings performance.

Neutral

Technical

58

The stock is trading near its recent highs, showing positive momentum over the past month, but some indicators suggest it is approaching resistance levels and could be due for consolidation.

FactorScore
Consumer Staples & Healthcare Exposure85
E-commerce & Direct-to-Consumer Trends70
Sustainability & Material Innovation75
Limited Exposure to High-Growth Tech40
Geographic Diversification80
FactorScore
Valuation70
Profitability75
Growth60
Balance Sheet Health85
Cash Flow90
Dividend Yield70
FactorScore
Trend Analysis70
Momentum50
Support & Resistance40
Moving Averages80
Volume60

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Consistent Earnings Beats

The company has consistently beaten earnings per share (EPS) estimates for the past several quarters, with surprise percentages ranging from 0.88% to 20.0%. This demonstrates a strong ability to manage operations and meet or exceed financial expectations.

Valuation chevron_right

Reasonable Price-to-Earnings (P/E) Ratio

The trailing twelve-month (TTM) P/E ratio is 29.58. While not low, it is within a reasonable range considering the company's market position and historical performance. The P/E for 2024 is 27.5, suggesting a more forward-looking valuation. Further analysis against industry peers is recommended.

Show More 🔒
thumb_down

Bearish Points (7)

Valuation Risk chevron_right

High Quarterly P/S Ratio

The quarterly Price-to-Sales (P/S) ratio for Q1 2025 is 11.0, and Q4 2024 is 12.1. These are significantly higher than the annual P/S ratios, suggesting potential overvaluation based on very recent performance or forward expectations that may not materialize.

Growth Deceleration chevron_right

Slowing Revenue Growth (Year-over-Year)

While annual revenue shows growth, the quarterly revenue figures show a slowdown (e.g., 848.09 million in Q4 2024 compared to 915.45 million in Q1 2024). Further analysis of year-over-year quarterly revenue growth is needed to confirm deceleration.

Show More 🔒

Calendar

July 2025

24

Ex-Dividend Date

August 2025

1

Next Earnings Date

EPS Est.
Revenue Est.

H: $1.61

A: $1.59

L: $1.57

H: 961.79M

A: 954.06M

L: 941.50M

August 2025

14

Next Dividend Date

Profile

Websiteaptar.com
Employees (FY)13K
ISIN-
FIGI-

AptarGroup, Inc. designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. It also provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases; elastomer for injectable primary packaging components; and active material science solutions. In addition, the company offers dispensing pumps, closures, elastomeric components, aerosol valves, and digital health solutions. It primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

Seasonals

2025
2024
2023
2022
2021

Price Target

175.00 USD

The 39 analysts offering 1 year price forecasts for ATR have a max estimate of 205.00 and a min estimate of 160.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
65.5M (99.17%)
Closely held shares
550K (0.83%)
66M
Free Float shares
65.5M (99.17%)
Closely held shares
550K (0.83%)

Capital Structure

Market cap
10.69B
Debt
1.08B
Minority interest
0.00
Cash & equivalents
223.84M
Enterprise value
11.54B

Valuation - Summary

Market Cap
10.7B
Net income
280M(2.62%)
Revenue
2.64B(24.75%)
10.7B
Market Cap
10.7B
Net income
280M(2.62%)
Revenue
2.64B(24.75%)
Price to earning ratio (P/E)38.20x
Price to sales ratio (P/S)4.00x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
3.58B
COGS
2.23B
Gross Profit
1.36B
OpEx
846.01M
Operating Income
509.5M
Other & Taxes
134.96M
Net Income
374.54M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒